You just read:

FDA Approves New 10 mg Dosing for XARELTO® (rivaroxaban) to Reduce the Continued Risk of Venous Thromboembolism (VTE)

News provided by

Janssen Pharmaceuticals, Inc.

Oct 30, 2017, 08:00 ET